1. ACR practice guideline for performing FDG-PET/CT in oncology.
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/nuc_med/fdg_pet_ct.aspx
. Accessed 10 Jan 2012
2. Agress H Jr, Wong TZ, Shreve P (2008) Interpretation and reporting of positron emission tomography-computed tomographic scans. Semin Ultrasound CT MR 29(4):283–90
3. Ak I, Stokkel MP, Pauwels EK (2000) Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 126(10):560–74
4. Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU (2001) Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 42(4):591–5
5. CMS released Transmittals R108 NCD; R1833 CP rescinding transmittals R106 NCD and R1817 CP.
http://www.cms.gov/transmittals/downloads/R108NCD.pdf
. Accessed 10 Jan 2012